Revive Therapeutics Ltd. (CSE: RVV, USA: RVVTF) is a life sciences company focused on the research and development of therapeutics for rare disorders and infectious diseases. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and was granted FDA orphan drug status designation for the use of CBD to treat auto-immune hepatitis (liver disease) and the use of CBD to treat ischemia and reperfusion injury from organ transplantation. With its recent acquisition of Psilocin Pharma Corp., Revive will advance Psilocybin-based therapeutics in various diseases and disorders and will prioritize development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. The Company is also exploring the use of Bucillamine for the potential treatment of infectious diseases, including COVID-19.
PSILOCIN pHARMA cORP., wholly-owned subsidiary
Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Its process encompassed with intellectual property that covers methods of production of Psilocybin based formulations. Visit psilocinpharma.com. Click here for press release regarding the acquisition.